Validation of serum neurofilaments as prognostic and potential pharmacodynamic biomarkers for ALSMichael Benatar, G. Garcia Gutierrez, Jaya Trivedi et al.|Neurology|2020Cited by 201
The Miami Framework for ALS and related neurodegenerative disorders: an integrated view of phenotype and biologyMichael Benatar, Tahseen Mozaffar, Joanne Wuu et al.|Nature Reviews Neurology|2024Cited by 40
Patient reported impact of symptoms in amyotrophic lateral sclerosis (PRISM-ALS): a national, cross-sectional studyChristine Zizzi, Chad Heatwole, Jamison Seabury et al.|EClinicalMedicine|2022Cited by 29
Machine learning suggests polygenic risk for cognitive dysfunction in amyotrophic lateral sclerosisKaterina Placek, Corey T. McMillan, Michael Benatar et al.|EMBO Molecular Medicine|2020Cited by 27
Harnessing the power of the electronic health record for <scp>ALS</scp> research and quality improvement: <scp>CReATe CAPTURE‐ALS</scp> and the <i><scp>ALS</scp> Toolkit</i>Volkan Granit, Michael Benatar, Anne‐Laure Grignon et al.|Muscle & Nerve|2021Cited by 8